Biosimilar therapies have already been in use in Canada for a few years, mostly in the chronic disease and supportive care settings. But soon they will be used for treating cancer as well. There isn’t a lot of information about these new oncology biosimilars and it’s important that breast cancer patients are aware of how their treatment plans may be impacted by these new therapies. We explore some of the emerging biosimilar therapies that will be used to treat cancer patients soon.

“Go UP the stairs.  Slide DOWN the slide.  No, Sweetie.  Go UP the STAIRS.”  She could barely walk, but she was climbing up the slide.  Then, and now.  Spend ten minutes at a playground, and the appeal of climbing up the face of the slide is undeniable.  I am acutely aware of the dangers of falling off the slide, the risks of children bumping into each other. I vaguely remember falling off a slide, decades ago--one of the old, tall ones—before playgrounds had soft surfaces.  I like to see everyone going in the same direction.  Up the stairs.  Down the slide.  Nice, orderly, predictable, and safe.

There’s been a lot of talk lately about new metastatic breast cancer treatments that can greatly extend the lives of many people in Canada. Targeted therapies are changing the landscape for mBC in a big way.

Adriana Capozzi of Bradford, Ontario, was diagnosed in October 2014 with HER2-positive, Stage III breast cancer.  She received four months of chemotherapy and one year of Herceptin, along with a bilateral mastectomy and 25 rounds of radiation.

For Shelley Scott of Winnipeg, a metastatic breast cancer diagnosis in November 2016 had a silver lining.

“It helped me appreciate the moments of my life rather than worrying about what might be, which is kind of a gift,” she says.

She tells the story of two coworkers she knew who planned a big trip for the time when they both were retired.  They never made the trip because one of them died.